Selecting Second-Line Treatment in HR+, HER2-Low Breast Cancer | Targeted Oncology

For patients with ESR1-mutated, hormone receptor (HR)-positive, HER2-low metastatic breast cancer, progression on initial CDK4/6 inhibitor-based therapy presents a key sequencing decision. Claudine Isaacs, MD, professor of medicine and oncology,…